GE Healthcare’s Invenia: Improving Breast Cancer Detection In Dense Breasts

GE Healthcare launched in June the Invenia Automated Breast Ultrasound System (ABUS), the first FDA-approved breast cancer screening option for women with dense breasts.

GE Healthcare, a unit of General Electric Co., launched in June the Invenia Automated Breast Ultrasound System (ABUS), the first FDA-approved breast cancer screening option for women with dense breasts. When used in addition to mammography, this promising new technology can improve breast cancer detection in this population by 35.7% and at an earlier, more treatable stage over mammography alone, according to a study used by the FDA to evaluate the device.

In the breast care continuum, there is screening, diagnosis, treatment, and follow-up. Mammography is the gold standard for breast cancer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight